NHS NEL
Demonstration Formulary
Demonstration Formulary
6 Endocrine system
06-01-01-02 Biphasic insulins
| Biphasic Insulin Lispro |
|
Formulary
|
BRANDS
|
|
| Insulin Lispro |
|
Formulary
|
|
|
|
Links
Answers to commonly asked questions about biosimilar versions of insulin glargine- BSSE APC Risk Assessment - High strength insulins/ Biosimilars/ Fixed combination
- DVLA guidance
For your patients who are currently prescribed Lantus®: A guide on how to use Lantus®.- For your patients who are currently prescribed Lantus®: A guide on how to use Lantus®.
- For your patients with diabetes who are currently prescribed Insuman® Basal: A step-by-step guide on how to use Insuman® Basal SoloStar.
- For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar.
- For your patients with diabetes who are currently prescribed Lantus ®: A step-by-step guide on how to use Lantus® SoloStar.
- For your patients with diabetes who are currently prescribed Toujeo® DoubleStar: A guide on how to use Toujeo® DoubleStar.
- For your patients with diabetes who are currently prescribed Toujeo® SoloStar: A guide on how to use Toujeo ® SoloStar.
- MHRA: Insulin degludec (Tresiba): available in additional higher strength
- NICE CG 28 Type 2 diabetes in adults: management NICE guideline
- NICE Guidance on prescribing
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- RICaD Insulin Degludec
- Risk Assessment - High Strength Insulins / Biosimilars / Fixed Combination
- The managed introduction of biosimilar Insulin Glargine (Semglee®▼) for patients with Type 2 Diabetes